Indication
Treatment of patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids.
Medicine details
- Medicine name:
- ruxolitinib (Jakavi)
- SMC ID:
- SMC2750
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- 03 March 2025